Applied BioCode (6598) — Capital Reinvestment Ratio

Latest as of September 2022: 1.89x

Applied BioCode (6598) has a Capital Reinvestment Ratio of 1.89x as of September 2022, meaning it reinvests 2% of its operating cash flow (NT$6.35 Million) in capital expenditures (NT$12.00 Million). See 6598 equity financing ratio to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

1.89x
Capex / Operating Cash Flow

Operating Cash Flow

NT$6.35 Million
TWD

Capital Expenditures

NT$12.00 Million
TWD

Data as of

Sep 2022
Most recent filing

Applied BioCode Capital Reinvestment Ratio (2022–2022)

This chart tracks Applied BioCode's Capital Reinvestment Ratio across 1 annual periods. Check 6598 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Applied BioCode (2022–2022)

Year-by-year Capital Reinvestment Ratio for Applied BioCode from 2022 to 2022. For live market cap and broader valuation context, see Applied BioCode stock valuation.

Year Reinvestment Ratio Operating CF (TWD) Capital Expenditures YoY Change
2022 0.15x NT$145.87 Million NT$22.14 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow